Spectroscopy in Ovarian Cancer

NCT04817449 | Completed

• 1 other identifier: 2020-21-12
• Study Type: observational
• Target: 160
• Locations: 1 country
• Sites: 1

Brief Summary

Ovarian cancer is the eighth most common cause of cancer death in the world. Advanced stage at diagnosis is associated with lower survival rates, thus early detection appears to have an important role. Raman Spectroscopy is a non-invasive technique that uses the interaction of light to identify the composition of the sample tested. The aim of the project is to explore the use of spectroscopic techniques in the detection of ovarian cancer. There are two different assessments within the project:

1. 1.Identify ovarian cancer in blood - Raman spectroscopic analysis will be performed on blood plasma taken from patients with suspected ovarian cancer.
2. 2.Detect active cancer within post chemotherapy fibrotic tissue - Ex vivo Raman spectroscopic analysis of peritoneal, omental or ovarian tissues collected from patients undergoing surgical treatment for ovarian cancer.

Conditions

Ovary Disease; Ovarian Cancer; Ovarian Neoplasms; Ovary Cyst

Outcome Measures

Primary Outcomes (2)

• Ascertain the diagnostic performance of vibrational spectroscopy for detection of Ovarian Cancer

  Biomarkers for ovarian cancer will be identified by analysing Raman spectral data of plasma samples taken from patient with ovarian cancer symptoms. Clinical outcome of cancer/no cancer will be used to correlate the results.

  2 years

• Ascertain the discriminatory ability of vibrational spectroscopy to differentiate between normal, fibrotic and cancerous tissue

  Samples taken from post chemotherapy patients will be analysed to identify the spectral signature of ovarian cancer in chemotherapy exposed tissue.

  2 years

Secondary Outcomes (2)

• Performance of vibrational spectroscopy in chemotherapy response prediction

  2 years

• Performance of vibrational spectroscopy in recurrence prediction

  2 years

Study Arms (1)

Suspected Ovarian Cancer

Patients referred or self presenting to secondary care with signs or symptoms of ovarian cancer.

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients presenting to secondary care with suspected ovarian cancer symptoms. Patients with likely ovarian cancer, yet to start definitive treatment.

You may qualify if:

• Female
• Symptoms suggestive of ovarian cancer
• Patients undergoing treatment of Ovarian Cancer

You may not qualify if:

• Less than 18 years of age
• Unable to consent to the study due to communication difficulties
• Unable to consent to the study due to lack of capacity

Sponsors & Collaborators

• University of Exeter: lead
• University Hospitals Bristol and Weston NHS Foundation Trust: collaborator

Study Sites (1)

University Hospitals Bristol and Weston NHS Trust

Bristol, United Kingdom

Location

Biospecimen

Retention: SAMPLES WITH DNA

Histological sections of tissue specimens of ovary, omentum or peritoneum Blood

MeSH Terms

Conditions

Ovarian Neoplasms; Ovarian Cysts; Ovarian Diseases

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Cysts

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 4, 2021
• First Posted: March 26, 2021
• Study Start: June 28, 2021
• Primary Completion: October 1, 2023
• Study Completion: October 30, 2025
• Last Updated: December 19, 2025

Record last verified: 2025-12

Locations

GB (1)